Skip to main content

Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis

Buy WaitHigh Confidence

Healthcare · Biotechnology

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of... Read more

$14.37+0.6% upside
Score 7.1/10Entry $13.79Target $14.45Reward/Risk 0.1:1

TrendMatrix rates Aurinia Pharmaceuticals Inc (AUPH) as Buy (Wait for Entry) with high confidence. The stock trades at $14.37 with +0.6% upside to the $14.45 price target. Overall score: 7.1/10 across 10 analysis dimensions. Reward/risk ratio: 0.1:1.

Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.

Val7.1Qual7.6Grw9.7Mom6.0Sent6.3Ins7.5Peer5.8Tech5.6Risk4.67.1OVERALL

Investment Thesis

+ V7 quality resilience bonus: +0.2 (Q=7.6 in RISK_OFF)
+ Sector modifier (): +1.2
+ Strong earnings beat streak (4/4)
- Cyclical risk: PE expanding 2.5x (earnings normalizing)
- Analyst target reached - limited upside remaining

Fundamentals

P/E (TTM)6.9
P/E (Fwd)17.0
Mkt Cap$1.9B
EV/EBITDA11.9
Profit Mgn101.5%
ROE59.9%
Rev Growth28.8%
Beta1.59
DividendNone
Analysts13
Frequently Asked Questions
Is AUPH stock a buy right now?

TrendMatrix rates Aurinia Pharmaceuticals Inc (AUPH) as Buy (Wait for Entry) with high confidence. Score 7.1/10. Entry target: $13.79.

What is the AUPH stock price target?

Take-profit target: $14.45 (+0.6% upside). Reward/risk ratio: 0.1:1. Stop-loss: $13.11.

What are the risks of investing in AUPH?

Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining.

Is AUPH overvalued or undervalued?

Aurinia Pharmaceuticals Inc trades at a P/E of 6.9 (forward 17.0). TrendMatrix value score: 7.1/10. Verdict: Buy (Wait for Entry).

What do analysts say about AUPH?

13 analysts cover AUPH with a consensus score of 3.9/5. Average price target: $17.

What does Aurinia Pharmaceuticals Inc do?Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with...

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Related stocks: NVAX (Novavax, Inc.) · INVA (Innoviva, Inc.) · INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I)
45 NEUTRAL
20d<50d200dGOLDEN CROSSSupp $13.52Res $15.24

Price Targets

$13
$14
$14
Upside+0.6%
Reward/Risk0.1:1

Position Sizing

ConvictionHIGH
Suggested %0.5%
Max %1%
RegimeRISK_OFF

Risk Alerts

! V8: Target reached (0.6% upside)
! ASYMMETRY:0.1<2.0
RANGE BOUNDSuitability: Aggressive
✓Momentum 6.0>=5.0
✓Insider activity: OK
✓No SEC red flags
✗Risk/Reward 0.1<2.0